List of Vaccines Companies in Japan - 14

AnGes was founded In December 1999, with the aim of developing hepatocyte growth factor (HGF) gene therapy drugs which can help regenerate blood vessels. Originating from the word angiogenesis meaning the formation of new blood vessels in English, our corporate name AnGes encapsulates our desire to be an angel (ange in French) offering new drugs for patients with hard-to-treat and rare diseases. Both our founder and our employees are still motivated by this desire.

The Biken Group is a Specialty Bio-Pharmaceutical Organization that contributes to public health through developing, manufacturing and supplying many of Japan's first vaccines, and also providing laboratory diagnostic services.

Research and development of biopharmaceuticals and bioproducts

A public biopharmaceutical company focused on developing novel cancer immunotherapies.

Nasal vaccine development for infectious diseases

Japan BCG Laboratory was established in 1952 and has produced high-quality BCG (Bacillus Calmette Guérin) vaccine ever since. Japan BCG Laboratory is the sole supplier of this vaccine in Japan. Working with UNICEF, WHO and the Pan American Health Organization (PAHO), Japan BCG Laboratory has distributed its BCG vaccine in more than 50 countries worldwide and has become a respected and longstanding supplier of high-quality products. Japan BCG Laboratory has supplied more than 2.25 billion doses of BCG vaccine for more than 50 years.

KAICO is a Japanese biotechnology start-up from Kyushu University, a national university in Japan. We focus on developing and producing recombinant proteins with the core technology, the silkworm-baculovirus expression system. Silkworms are unique insects that can create recombinant proteins within its body. With the silkworm-baculovirus expression system, KAICO uses silkworms as a bioreactor to express diverse recombinant proteins that are hard to extract using other systems, for example, microbes and cells.   Regarding production, distinctive characteristics of the silkworm-baculovirus expression systems are scalability and speediness. It takes less than a week to express target proteins within the body of silkworms. To scale up its production, we increase the number of silkworms. Unlike other expression systems, we do not require bio tanks for scale-up. This makes a speedy transition possible from the research and development phase to mass production.   KAICO’s development programs currently include oral vaccines that are not only for human use but also for animals. An oral vaccine can raise the antibody titer by eating instead of injection. Proteins are decomposed into amino acids when ingested orally. However, KAICO found that even when administered orally, the antibody titer of some proteins expressed in silkworms can be increased.   Through the spread of oral vaccines, we aim to contribute to global public health for human beings and improve the productivity of livestock farmers.   As for human use, compared to injectable vaccines, it has significant merits as follows: 1. No need for syringes and needles. 2. No need for medical personnel for inoculation. 3. No need for cold-chain transportation and storage. By bringing in oral vaccines, KAICO will change the world with silkworms.

KM Biologics' history of vaccine production started with the smallpox vaccine over a half century ago. Since then, we have produced many vaccines including those for typhoid and typhus, and have contributed to the eradication of infectious diseases in Japan. In recent years, through collaborating with companies and universities in Japan and overseas, we have been working on the development of new vaccines such as cell culture-derived influenza vaccines and DPT-based combined vaccines.

OncoTherapy Science, Inc. provides pharmaceutical companies with yielded drug candidates by using outcomes obtained from joint research with universities and companies. These outcomes include oncogene information isolated by comprehensive analysis of genes specifically expressed in cancer cells and functional analysis information of proteins produced by oncogenes and other gene products. We have also been performing research and development business regarding medications.

The purpose of the Shionogi Group's corporate activities is, as expressed in the opening of its Company Policy, to "supply the best possible medicine to protect the health and wellbeing of the patients we serve."​ This eternal and unwavering corporate philosophy is a statement of our vision and value to society. To achieve and live by the Company Policy, we have formulated Action Guidelines, which all Shionogi employees share and embrace as norms for daily activities. Through activities based on the Company Policy and the Action Guidelines, Shionogi will continue to contribute to patients, physicians and other healthcare providers, shareholders and investors, and furthermore to society as a whole.

Takara Bio Inc. is committed to improving the human condition through biotechnology. Starting as the biomedical business of Takara Shuzo, a fermentation and beverage company founded in 1925 (now Takara Holdings Company, Inc.), Takara Bio has focused on developing research tools for the life sciences, cell and gene therapy technologies, and nutraceuticals since its launch in 1967. The three business units of TAKARA BIO INC are: • Genetic Engineering Research - manufactures and sells research reagents and scientific instruments used by biotechnology researchers worldwide, as well as contract research services. • Agribio - produces and sells health food products whose functionality have been proven by biotechnology, and conducts a mushroom business based on technologies for large-scale mushroom production. • Gene Medicine - conducts clinical development projects to work toward commercializing cell and gene therapies centered on a highly efficient gene transduction method and a lymphocyte expansion-culture system, both using RetroNectin® reagent.

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

UMN Pharma Co., Ltd. is a bioventure company established in April 2004. The company name is Unmet Medical Needs (UMN), and the company is currently focusing on developing and manufacturing vaccines to prevent infectious diseases.

We will create immunotherapy using nanotechnology as a new treatment option for intractable cancers and viral infections.Uniting Immunity and Nanotechnology for Fighting Cancer and Infectious Diseases